$1 test more effective than PSA screen for prostate cancer
A University of Central Florida scientist has developed an easy-to-use, inexpensive prostate cancer test that has shown to be more accurate that the standard PSA test for prostate cancer.
The test works by using gold nanoparticles to detect the antibodies that are produced when a cancerous tumor begins to develop. When a few drops of blood serum from a finger prick are mixed with the gold nanoparticles, certain cancer biomarkers cling to the surface of the tiny particles, increasing their size and causing them to clump together. The size of those clumps, the researchers say, can reveal whether a patient has prostate cancer and how advanced it may be.
The team explained that that this test is unique because it’s a simple process and the material used to conduct it costs less than $1. The test has shown to determine with 90 to 95 percent confidence that the result is not false-positive, and 50 percent confidence when it comes to false-negatives, which is higher than the PSA test’s 20 percent false-negative score.
The research team, under Dr. Qun "Treen" Huo, will study the new test in clinical settings, with hopes of bringing it to market in two to three years.